The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
NCT02336607 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 529
Last updated 2015-03-23
Summary
The purpose of this study is to evaluate the effects on blood pressure control, pulse wave velocity, as well as safety and tolerability of felodipine single or combine with other drugs in Chinese Hypertension patients.
Conditions
Interventions
- DRUG
-
Felodipine tablet (Plendil) alone
Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
- DRUG
-
Felodipine tablet (Plendil)+Hydrochlorothiazide
Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
- DRUG
-
Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
- DRUG
-
Felodipine tablets (Plendil)+Lisinopril (Zestril)
Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ningling Sun, PhD, MD · Beijing University People's Hospital, Department of Cardiology
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Max Age
- 79 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-12-31
- Primary Completion
- 2006-06-30
- Completion
- 2006-08-31
More Related Trials
-
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
NCT07051603 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine
NCT00626743 ·Status: COMPLETED ·Phase: PHASE1
-
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
NCT03015311 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients
NCT03946514 ·Status: COMPLETED ·Phase: PHASE4
-
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
NCT06465264 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension
NCT00562614 ·Status: COMPLETED ·Phase: PHASE2
-
The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People
NCT03255993 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
NCT01848873 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension
NCT00562549 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
NCT03756103 ·Status: COMPLETED ·Phase: PHASE2
-
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
NCT06423352 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
NCT01011660 ·Status: UNKNOWN ·Phase: PHASE4
-
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
NCT03264352 ·Status: RECRUITING ·Phase: PHASE4
-
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
NCT04974151 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
NCT01663233 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
NCT01131546 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety
NCT03667677 ·Status: UNKNOWN ·Phase: PHASE4
-
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT03226340 ·Status: UNKNOWN ·Phase: PHASE4
-
Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers
NCT03128138 ·Status: COMPLETED ·Phase: PHASE1
-
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
NCT02213224 ·Status: UNKNOWN ·Phase: PHASE4
-
Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
NCT01819441 ·Status: UNKNOWN ·Phase: PHASE4
-
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
NCT00642096 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
NCT00425373 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Irbesartan and Amlodipine Combination in Controlling Blood Pressure
NCT00950066 ·Status: COMPLETED ·Phase: PHASE2